Amgen Research Munich GmbH

Core competencies

Micromet puts novel concepts in immunotherapy to work. Using proprietary technologies, the Company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. Two candidates are currently in clinical trials. The Company has established a powerful drug development platform: BiTETM ('Bispecific T cell engagers'), a unique drug format that leverages the outstanding cytotoxic potential of T cells to precisely eliminate pathogenic cells. In addition, Micromet is exploiting the potential of SCAs (single-chain antibodies) for the development of novel drug candidates. The Company has attracted both top-tier life science investors and corporate partners such as MedImmune, Inc., Enzon Pharmaceuticals, Inc., and Serono.

Key sectors / sub-sectors

• Biotechnology: Prophylactic drug development
• Biotechnology: Therapeutic drug development

NACE industries

• Other research and experimental development on natural sciences and engineering 72.19

Certifications

not available

Sales markets - target industries

not available

Sales markets - target countries

not available

Cooperation offers

not available